US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

SIMPLIFY CHINA A SHARES PLUS INCOME ETF

28.46

-0.5563-1.92%

Volume:1.01K

Turnover:28.94K

Market Cap:818.34M

PE:- -

High:28.68

Open:28.68

Low:28.46

Close:29.02

Loading ...

Overview Company News Filings

Verimatrix Announces Release of DVB ReAccess Over-the-Air CAS Retrofit Solution

Newmont Stock Loses 27% in 3 Months: Should You Buy Now?

Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease

ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease

Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease

NSPR Stock May Gain as First Patient Enrolls in CGUARDIANS II Study

BILL Unveils 1099 Form Filing Solution for SMBs

Newmont Stock Skids 30% From Its 52-Week High: Should You Buy the Dip?

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CAS/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CAS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CAS\",,,,,undefined,":{"symbol":"CAS","market":"US","secType":"STK","nameCN":"SIMPLIFY CHINA A SHARES PLUS INCOME ETF","latestPrice":28.4639,"timestamp":1749844800000,"preClose":29.0202,"halted":0,"volume":1009,"delay":0,"floatShares":375001,"shares":28750000,"eps":0,"marketStatus":"Market Closed","change":-0.5563,"latestTime":"06-13 16:00:00 EDT","open":28.68,"high":28.68,"low":28.4639,"amount":28936.5,"amplitude":0.007447,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1750060800000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"AMEX","adjPreClose":29.0202,"sharesOutstanding":375001,"nav":29.16,"aum":10936178.87,"bidAskSpread":0,"volumeRatio":2.094229318940644},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CAS\",,,,,undefined,":{"symbol":"CAS","floatShares":375001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":2.094229318940644,"shares":28750000,"dividePrice":0,"high":28.68,"amplitude":0.007447,"preClose":29.0202,"low":28.4639,"week52Low":21.9325,"pbRate":"--","week52High":29.4715,"institutionHeld":0.8889,"latestPrice":28.4639,"eps":0,"divideRate":0,"volume":1009,"delay":0,"ttmEps":0,"open":28.68,"prevYearClose":25.05,"prevWeekClose":28.942,"prevMonthClose":28.5656,"prevQuarterClose":25.4652,"fiveDayClose":28.942,"twentyDayClose":28.9258,"sixtyDayClose":27.4093},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CAS\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2503484505","title":"Verimatrix Announces Release of DVB ReAccess Over-the-Air CAS Retrofit Solution","url":"https://stock-news.laohu8.com/highlight/detail?id=2503484505","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503484505?lang=en_us&edition=fundamental","pubTime":"2025-01-15 00:45","pubTimestamp":1736873100,"startTime":"0","endTime":"0","summary":"Verimatrix DVB Access completes Cartesian’s Farncombe Security Audit. AIX-EN-PROVENCE, France & SAN DIEGO, January 14, 2025----Regulatory News:. Verimatrix, , the leader in powering the modern connected world with people-centered security, today announced general availability of its new DVB ReAccess solutions that serves as a uniquely powerful over-the-air  Conditional Access System . The solution also provides users with added peace of mind following the recent completion of Cartesian’s Farncombe Security Audit.Verimatrix DVB ReAccess is a well-tested OTA CAS retrofit solution that can be downloaded over the air into deployed devices as a replacement of an incumbent CAS, without requiring any device swap, nor any physical intervention. To mitigate all the constraints related to its OTA nature, DVB ReAccess implements a number of white box cryptography and code protection techniques, areas on which Verimatrix has long-established experience.\"The security innovations within DVB ReAccess","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/verimatrix-announces-release-dvb-reaccess-164500850.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CAS","BK4187","ISDCF","BK4097","AIRI"],"gpt_icon":0},{"id":"2502049473","title":"Newmont Stock Loses 27% in 3 Months: Should You Buy Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2502049473","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502049473?lang=en_us&edition=fundamental","pubTime":"2025-01-09 22:00","pubTimestamp":1736431200,"startTime":"0","endTime":"0","summary":"Given the significant pullback in NEM’s shares, investors might be tempted to snap up the stock. But is this the right time to buy NEM?Key Projects & Newcrest Buyout to Aid NEM’s Growth. Newmont continues to invest in growth projects in a calculated manner. The company is pursuing several projects, including Tanami Expansion 2 in Australia, the Ahafo North expansion in Ghana and Cadia Panel Caves in Australia. These projects should expand production capacity and extend mine life, driving revenues and profits.The acquisition of Newcrest Mining Limited has also created an industry-leading portfolio with a multi-decade gold and copper production profile in the most favorable mining jurisdictions globally. The combination of Newmont and Newcrest is expected to deliver significant value for shareholders and generate meaningful synergies. NEM has achieved $500 million in annual run-rate synergies following the Newcrest buyout.Newmont also remains committed to divesting non-core businesses as","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/newmont-stock-loses-27-3-140000248.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0300736062.USD","LU0612318385.USD","LU0498741890.SGD","LU0055631609.USD","LU1883866441.USD","LU0330918003.SGD","LU0278409577.USD","BK4017","KGC","LU0345780281.USD","LU0630314457.HKD","LU2462611646.USD","AEM","LU0724618789.USD","SG9999001143.SGD","BK4532","LU0612318971.USD","LU0496367417.USD","BK4533","LU0788109121.HKD","BK4585","LU0345770993.USD","LU0345781412.USD","LU0456854461.SGD","LU0788108826.HKD","NEM","LU0368265764.SGD","LU0075056555.USD","LU1223082196.USD","LU1023059493.AUD","LU0345770308.USD","LU0266512127.USD","LU0640476718.USD","BK4570","LU1223083913.SGD","LU1430597077.USD","NEM.AU","LU1169589451.USD","LU0498741114.HKD","LU0345780521.USD","BK4588","CAS","LU1223082519.USD","LU2498475776.HKD","LU1169590202.USD","LU1280957306.USD","LU0300736492.USD","LU0654597011.USD","LU0345780950.USD","GOLD"],"gpt_icon":0},{"id":"2501725139","title":"Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2501725139","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501725139?lang=en_us&edition=fundamental","pubTime":"2025-01-08 20:00","pubTimestamp":1736337600,"startTime":"0","endTime":"0","summary":"- Veligrotug, with recent positive phase 3 topline data in both active and chronic thyroid eye disease , has the potential to transform the standard of care in TED with a differentiated clinical profile achieved with less drug and fewer infusions; Biologics License Application  submission on track for second half of 2025 -. - REVEAL-1 and REVEAL-2, phase 3 clinical trials for subcutaneous  VRDN-003 in active and chronic TED respectively, are currently dosing patients; topline data for both trials, which are evaluating VRDN-003 dosed Q4W or Q8W, is on track for the first half of 2026 -. \"In addition to TED, we are equally excited by the potential of our FcRn inhibitor portfolio. In Q3 of this year, we anticipate showing proof-of-concept data, including IgG reduction, from our planned VRDN-006 phase 1 clinical trial in healthy volunteers. We also continue to advance our bispecific, half-life extended, potential best-in-class VRDN-008 program. We previously showed that, in non-human prima","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/viridian-therapeutics-highlights-2025-corporate-120000824.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["VRDN","LENZ","LDL","THAC","BK4139","PD","CAS","LU1169590202.USD","LU1169589451.USD","BK4023"],"gpt_icon":0},{"id":"2501267322","title":"ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2501267322","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501267322?lang=en_us&edition=fundamental","pubTime":"2025-01-07 05:00","pubTimestamp":1736197200,"startTime":"0","endTime":"0","summary":"Totality of data observed with subcutaneous lonigutamab in Thyroid Eye Disease (TED) patients demonstrate potential for efficacy in line with standard of care and a more favorable safety profile Condu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/06/3004952/0/en/ACELYRIN-INC-Announces-Additional-Phase-2-Data-and-Phase-3-Program-Design-for-Lonigutamab-in-Thyroid-Eye-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INC","BK4139","CAS","SLRN"],"gpt_icon":0},{"id":"2491660734","title":"Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2491660734","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491660734?lang=en_us&edition=fundamental","pubTime":"2024-12-16 20:00","pubTimestamp":1734350400,"startTime":"0","endTime":"0","summary":"- Veligrotug met all primary and secondary endpoints with high statistical significance in THRIVE-2, achieving a week 15 proptosis responder rate  of 56%  -. - THRIVE-2 is the first global phase 3 study in patients with chronic TED to demonstrate a statistically significant and clinically meaningful 56% diplopia responder rate  and 32% rate of diplopia complete resolution  -. - Veligrotug was generally well-tolerated with 94% of patients completing their treatment course and a 9.6% placebo-adjusted rate of hearing impairment -. \"We are extremely pleased to announce better-than-expected THRIVE-2 results generated in the broadest population of chronic TED patients studied in a global phase 3 study to date. We believe that these efficacy and safety results in only five infusions, combined with our compelling data from THRIVE, confirm the potential of veli to be the treatment-of-choice for all forms of active and chronic TED,\" said Steve Mahoney, Viridian’s President and CEO. \"The robustne","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/oJYBj0e077WL3.gH1kM25Q--~B/aD02MDA7dz0yNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/56204b802211bd79a80bc345712ac81f","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/oJYBj0e077WL3.gH1kM25Q--~B/aD02MDA7dz0yNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/56204b802211bd79a80bc345712ac81f"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/viridian-therapeutics-announces-positive-topline-120000827.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["VRDN","CAS","LENZ","THAC","BK4139"],"gpt_icon":0},{"id":"2490894559","title":"NSPR Stock May Gain as First Patient Enrolls in CGUARDIANS II Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2490894559","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490894559?lang=en_us&edition=fundamental","pubTime":"2024-12-12 01:17","pubTimestamp":1733937420,"startTime":"0","endTime":"0","summary":"InspireMD Inc. NSPR recently announced the first patient enrolment in the company’s CGUARDIANS II clinical trial. The trial evaluates NSPR’s CGuard Prime Carotid Stent System in patients undergoing carotid artery stenting via the Transcarotid Artery Revascularization  approach.CGUARDIANS II is a prospective, multi-center, single-arm pivotal study that aims to enroll a minimum of 50 evaluable patients. This study aims to evaluate the acute device success and technical success of the CGuard Prime when used in conjunction with an FDA-cleared TCAR neuro-protection system in patients at high risk for adverse events from carotid endarterectomy.The CGuard Prime Carotid Stent system is optimized for TCAR procedures, offering a less invasive alternative to traditional carotid artery surgery. This system’s advanced neuroprotective features ensure that patients with high risk for carotid endarterectomy have a safe and effective treatment option. The CGuard’s design minimizes the risk of complicat","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/vZlajmbYZzKfSC9h66RaJg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ae98f9f4477af1de31a0a61cde692d41","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/vZlajmbYZzKfSC9h66RaJg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ae98f9f4477af1de31a0a61cde692d41"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nspr-stock-may-gain-first-171700184.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2720916845.USD","LU0205193047.USD","LU0240878834.USD","BK4198","LU2065732104.USD","MASI","BK4082","LU2764263203.CNY","IE0009354923.USD","GMED","LU0205194284.USD","NSPR","ANGO","LU2764263039.SGD","CAS","LU0240877869.USD","LU2764262908.HKD"],"gpt_icon":0},{"id":"2490157180","title":"BILL Unveils 1099 Form Filing Solution for SMBs","url":"https://stock-news.laohu8.com/highlight/detail?id=2490157180","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490157180?lang=en_us&edition=fundamental","pubTime":"2024-12-10 21:55","pubTimestamp":1733838900,"startTime":"0","endTime":"0","summary":"BILL’s all-in-one financial operations platform introduces 1099 Form Filing to simplify one of the most important and cumbersome aspects of running a business – tax compliance. SAN JOSE, Calif., December 10, 2024----BILL , a leading financial operations platform for small and midsize businesses , today announced a new 1099 Filing offering that allows SMBs to simplify their 1099 taxes within the BILL Financial Operations Platform. With these new capabilities as part of BILL’s flagship accounts payable  solution, SMBs and the accounting professionals who serve them can now quickly and easily prepare and file their 1099 forms in the same place they pay and manage their vendors year-around.Delivering a Simplified 1099 Tax Experience for SMBs. According to the 2022 CPA.com & AICPA PCPS Client Advisory Services  Benchmark Survey, CAS practitioners indicated that 1099 creation and filing was the most in-demand CAS service to help their SMB clients, demonstrating the need for 1099-specific tax","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ym_JzFLoz6mxvMVADr14XQ--~B/aD0yOTM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/1154dfc319809a3a312c1a6df5b1b707","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ym_JzFLoz6mxvMVADr14XQ--~B/aD0yOTM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/1154dfc319809a3a312c1a6df5b1b707"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bill-unveils-1099-form-filing-135500060.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4551","AP","BILL","CAS","BK4585","BK4023","BK4535","BK4588","BK4006"],"gpt_icon":0},{"id":"2490720314","title":"Newmont Stock Skids 30% From Its 52-Week High: Should You Buy the Dip?","url":"https://stock-news.laohu8.com/highlight/detail?id=2490720314","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490720314?lang=en_us&edition=fundamental","pubTime":"2024-12-09 20:04","pubTimestamp":1733745840,"startTime":"0","endTime":"0","summary":"Is the time right to buy NEM’s shares for potential upside?Let’s take a look at the stock’s fundamentals.Key Projects & Newcrest Buyout to Catalyze NEM’s Growth","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/G5XrE0LCS4YCOUlUAoD4SQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/aaa340faeefa7ee40b3aaf505e5e01be","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/G5XrE0LCS4YCOUlUAoD4SQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/aaa340faeefa7ee40b3aaf505e5e01be"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/newmont-stock-skids-30-52-120400216.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["LU0640476718.USD","LU0612318385.USD","LU0788109121.HKD","NEM","LU1883866441.USD","LU1169589451.USD","GOLD","LU0498741114.HKD","LU1023059493.AUD","LU0345781412.USD","LU0654597011.USD","BK7104","LU0278409577.USD","LU0788108826.HKD","BK4533","BK7054","LU0345770993.USD","LU0456854461.SGD","LU1430597077.USD","LU0075056555.USD","LU0345780950.USD","LU0330918003.SGD","CAS","LU0345770308.USD","LU1223082519.USD","NEM.AU","LU0345780521.USD","BK4570","LU0612318971.USD","BK7506","LU0300736062.USD","LU1169590202.USD","AEM","LU0368265764.SGD","KGC","LU1223082196.USD","BK4585","SG9999001143.SGD","LU0630314457.HKD","LU1223083913.SGD","GOLD.AU","BK4532","LU0724618789.USD","LU0300736492.USD","NCM.AU","LU0498741890.SGD","LU0496367417.USD","BK4017","LU2462611646.USD","LU0345780281.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":28,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CAS\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CAS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CAS\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CAS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CAS","date":"2022-06-06","current":24.303082,"percent":0.981982,"low":-15.393463,"twenty":-15.286351,"median":-15.225145,"eighty":19.164674,"high":24.31512,"avg":-7.79187,"sd":14.434016,"marketCap":290231250},"quantilePoints":[{"date":"2021-07-16","current":-15.133335,"twenty":-15.157817,"median":-15.133335,"eighty":-15.116503,"marketCap":284337500},{"date":"2021-07-23","current":-15.118033,"twenty":-15.151696,"median":-15.125684,"eighty":-15.108852,"marketCap":284050000},{"date":"2021-07-30","current":-15.133335,"twenty":-15.137619,"median":-15.133335,"eighty":-15.108852,"marketCap":284337500},{"date":"2021-08-06","current":-15.133335,"twenty":-15.137619,"median":-15.133335,"eighty":-15.116503,"marketCap":284337500},{"date":"2021-08-13","current":-15.102731,"twenty":-15.148636,"median":-15.133335,"eighty":-15.116503,"marketCap":283762500},{"date":"2021-08-20","current":-15.056826,"twenty":-15.137619,"median":-15.133335,"eighty":-15.102731,"marketCap":282900000},{"date":"2021-08-27","current":-15.133335,"twenty":-15.134253,"median":-15.133335,"eighty":-15.102731,"marketCap":284337500},{"date":"2021-09-03","current":-15.133335,"twenty":-15.133335,"median":-15.133335,"eighty":-15.102731,"marketCap":284337500},{"date":"2021-09-10","current":-15.056826,"twenty":-15.133335,"median":-15.133335,"eighty":-15.102731,"marketCap":282900000},{"date":"2021-09-17","current":-15.194541,"twenty":-15.148636,"median":-15.133335,"eighty":-15.102731,"marketCap":285487500},{"date":"2021-09-24","current":-15.102731,"twenty":-15.163938,"median":-15.133335,"eighty":-15.102731,"marketCap":283762500},{"date":"2021-10-01","current":-15.271049,"twenty":-15.194541,"median":-15.133335,"eighty":-15.102731,"marketCap":286925000},{"date":"2021-10-07","current":-15.240446,"twenty":-15.194541,"median":-15.133335,"eighty":-15.108852,"marketCap":286350000},{"date":"2021-10-15","current":-15.225145,"twenty":-15.203722,"median":-15.133335,"eighty":-15.113442,"marketCap":286062500},{"date":"2021-10-22","current":-15.194541,"twenty":-15.209843,"median":-15.133335,"eighty":-15.118033,"marketCap":285487500},{"date":"2021-10-29","current":-15.240446,"twenty":-15.225145,"median":-15.148636,"eighty":-15.118033,"marketCap":286350000},{"date":"2021-11-05","current":-15.248097,"twenty":-15.240446,"median":-15.156287,"eighty":-15.118033,"marketCap":286493750},{"date":"2021-11-12","current":-15.255748,"twenty":-15.255748,"median":-15.163938,"eighty":-15.118033,"marketCap":286637500},{"date":"2021-11-19","current":-15.240446,"twenty":-15.255748,"median":-15.173043,"eighty":-15.118033,"marketCap":286350000},{"date":"2021-11-26","current":-15.271049,"twenty":-15.255748,"median":-15.194541,"eighty":-15.118033,"marketCap":286925000},{"date":"2021-12-03","current":-15.271049,"twenty":-15.255748,"median":-15.194541,"eighty":-15.118064,"marketCap":286925000},{"date":"2021-12-10","current":-15.240446,"twenty":-15.255748,"median":-15.194541,"eighty":-15.121216,"marketCap":286350000},{"date":"2021-12-17","current":-15.225145,"twenty":-15.255748,"median":-15.209843,"eighty":-15.133335,"marketCap":286062500},{"date":"2021-12-23","current":-15.209843,"twenty":-15.255748,"median":-15.209843,"eighty":-15.133335,"marketCap":285775000},{"date":"2021-12-31","current":-15.240446,"twenty":-15.255748,"median":-15.209843,"eighty":-15.133335,"marketCap":286350000},{"date":"2022-01-07","current":-15.240446,"twenty":-15.255748,"median":-15.209843,"eighty":-15.133335,"marketCap":286350000},{"date":"2022-01-14","current":-15.255748,"twenty":-15.255748,"median":-15.212673,"eighty":-15.133335,"marketCap":286637500},{"date":"2022-01-21","current":-15.286351,"twenty":-15.255748,"median":-15.225145,"eighty":-15.133335,"marketCap":287212500},{"date":"2022-01-28","current":-15.271049,"twenty":-15.258808,"median":-15.225145,"eighty":-15.133335,"marketCap":286925000},{"date":"2022-02-04","current":-15.301653,"twenty":-15.271049,"median":-15.225145,"eighty":-15.133335,"marketCap":287500000},{"date":"2022-02-11","current":-15.316954,"twenty":-15.271049,"median":-15.225145,"eighty":-15.133335,"marketCap":287787500},{"date":"2022-02-18","current":-15.332256,"twenty":-15.271049,"median":-15.240446,"eighty":-15.133335,"marketCap":288075000},{"date":"2022-02-25","current":-15.347558,"twenty":-15.28176,"median":-15.240446,"eighty":-15.133335,"marketCap":288362500},{"date":"2022-03-04","current":-15.362859,"twenty":-15.286351,"median":-15.240446,"eighty":-15.133335,"marketCap":288650000},{"date":"2022-03-11","current":-15.35429,"twenty":-15.286351,"median":-15.240446,"eighty":-15.133335,"marketCap":288489000},{"date":"2022-03-18","current":-15.362859,"twenty":-15.294002,"median":-15.240599,"eighty":-15.133335,"marketCap":288650000},{"date":"2022-03-25","current":-15.362859,"twenty":-15.301653,"median":-15.246873,"eighty":-15.134253,"marketCap":288650000},{"date":"2022-04-01","current":19.267894,"twenty":-15.301653,"median":-15.245649,"eighty":-15.133335,"marketCap":289800000},{"date":"2022-04-08","current":19.21055,"twenty":-15.301653,"median":-15.240599,"eighty":-15.133335,"marketCap":288937500},{"date":"2022-04-14","current":19.223739,"twenty":-15.301653,"median":-15.240446,"eighty":-15.133335,"marketCap":289135875},{"date":"2022-04-22","current":19.267894,"twenty":-15.301653,"median":-15.240446,"eighty":-15.133335,"marketCap":289800000},{"date":"2022-04-29","current":19.24878,"twenty":-15.298593,"median":-15.240446,"eighty":-15.118033,"marketCap":289512500},{"date":"2022-05-06","current":19.229665,"twenty":-15.294002,"median":-15.240446,"eighty":-15.118033,"marketCap":289225000},{"date":"2022-05-13","current":19.13409,"twenty":-15.290942,"median":-15.225145,"eighty":-15.102731,"marketCap":287787500},{"date":"2022-05-20","current":19.287009,"twenty":-15.286351,"median":-15.225145,"eighty":-15.102731,"marketCap":290087500},{"date":"2022-05-27","current":24.291045,"twenty":-15.286351,"median":-15.225145,"eighty":-15.056826,"marketCap":290087500},{"date":"2022-06-03","current":24.291045,"twenty":-15.286351,"median":-15.225145,"eighty":19.149382,"marketCap":290087500},{"date":"2022-06-06","current":24.303082,"twenty":-15.286351,"median":-15.225145,"eighty":19.164674,"marketCap":290231250}],"updateTime":1749936898082}}}